US OptionsDetailed Quotes

FHTX240816C5000

Watchlist

1.05
0.000.00%

15min DelayClose Jul 25 15:51 ET

0.00High0.00Low

Foghorn Therapeutics Stock Discussion

Jaguar8

May 20 08:54

$Foghorn Therapeutics(FHTX.US)$
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Trytosaveabit

Apr 9 15:59

Update! Watching

$Foghorn Therapeutics(FHTX.US)$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...

Jaguar8

Apr 9 15:32

$Foghorn Therapeutics(FHTX.US)$
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.

Moomoo AI

Mar 10 08:40

Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Analysts Just Slashed This Year's Estimates

Stock_Drift

Mar 9 05:32

Some Top Movers 🚨 3/8/2024

$Foghorn Therapeutics(FHTX.US)$ $WideOpenWest(WOW.US)$ $Rezolute(RZLT.US)$ $Fitell(FTEL.US)$ $Alliance Entertainment Holding(AENT.US)$ $HomeStreet(HMST.US)$ $Loma Negra(LOMA.US)$ $Monogram Orthopaedics(MGRM.US)$ $Blaze Minerals Ltd(BLZ.AU)$ $DoubleDown Interactive(DDI.US)$

Moomoo AI

Feb 15 05:16

Foghorn Therapeutics' low P/S ratio may be due to investor skepticism about sustained strong revenue. The company's forecasted growth, lower than the industry average, could be causing shareholder unease and potentially impeding a strong share price rise.